Solventum (SOLV) Stock Price, News & Analysis

Company Overview

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

Key Stats

• Today's Range: $71.51 to $73.27
• 50-Day Range: $48.22 to $72.33
• 52-Week Range: $47.16 to $96.05
• Volume: 679,520 shs
• Average Volume: 1.95 million shs
• Market Capitalization: $12.46 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $58.25
• Consensus Rating: Reduce

Solventum Stock Analysis - MarketRank™

Solventum scored higher than 23% of companies evaluated by MarketBeat, and ranked 904th out of 1,015 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Solventum has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Solventum has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -11.44%

Earnings Growth

Earnings for Solventum are expected to decrease by -11.44% in the coming year, from $6.38 to $5.65 per share.

Price to Earnings Growth Ratio

Solventum has a PEG Ratio of 1.54. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.87% of the float of Solventum has been sold short.

Short Interest Ratio / Days to Cover

Solventum has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Solventum has recently increased by 1.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solventum does not currently pay a dividend.

Dividend Growth

Solventum does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.87% of the float of Solventum has been sold short.

Short Interest Ratio / Days to Cover

Solventum has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Solventum has recently increased by 1.33%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.14

News Sentiment

Solventum has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Solventum this week, compared to 6 articles on an average week.

Search Interest

Only 15 people have searched for SOLV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Solventum to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solventum insiders have not sold or bought any company stock.

SOLV Stock Analysis - Frequently Asked Questions

How have SOLV shares performed this year?

Solventum's stock was trading at $66.90 at the start of the year. Since then, SOLV shares have increased by 7.8% and is now trading at $72.13.
View the best growth stocks for 2024 here.

How were Solventum's earnings last quarter?

Solventum Co. (NYSE:SOLV) posted its earnings results on Thursday, August, 8th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.10. The company's quarterly revenue was up .2% compared to the same quarter last year.

Who are Solventum's major shareholders?

Top institutional investors of Solventum include Davis Selected Advisers (2.99%), Nuance Investments LLC (1.27%), Newport Trust Company LLC (1.08%) and Baupost Group LLC MA (1.05%).

How do I buy shares of Solventum?

Shares of SOLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:SOLV
• Previous Symbol: :
• CUSIP: N/A
• CIK: 1964738
• Web: www.solventum.com
• Phone: 651-733-1110
• Fax: N/A
• Employees: 22,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $58.25
• High Stock Price Target: $64.00
• Low Stock Price Target: $54.00
• Potential Upside/Downside: -19.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 11.31
• P/E Growth: 1.54
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 2.90
• Current Ratio: 1.31
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $8.25 billion
• Price / Sales: 1.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 172,710,000
• Free Float: N/A
• Market Cap: $12.46 billion
• Optionable: Optionable
• Beta: N/A